ACALABRUTINIB

Brand name:

• Calquence®

Pharmaceutical company:

AstraZeneca Pty Ltd

Condition/indication:
(therapeutic use)

• Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)

PBAC Submission type:

Change to listing (–)

Comment:

--

Public Summary Document:

Public Summary Documents – November 2021

Related medicines:

• ACALABRUTINIB
• ACALABRUTINIB

Submission received for:

November 2021 PBAC meeting

Opportunity for consumer comment:

Open 28/07/2021 and close 22/09/2021 (see PBS Website)

PBAC meeting:

Held on 03/11/2021

PBAC outcome published:

Not Recommended (see PBAC Outcomes)

Lodgement of required documentation:

Not applicable

Agreement to listing arrangements:

Not applicable

Government processes:

Not applicable

Medicine listed on the PBS:

Not applicable

---